Beverly Hills Plastic Surgeon Dr. David Sayah Reports Growing Demand for Breast Implant Removal and BBL Reversal

Beverly Hills plastic surgeon David Sayah reports increased patient interest in revision procedures—including breast implant removal, breast revision and BBL reversal—to restore more natural proportions. National breast implant removals were essentially flat at 41,271 in 2024 versus 41,115 in 2023, while a 2025 study of 123 BBL revision or buttock-reduction patients characterized demand as increasingly popular. The release is practice-level commentary rather than evidence of a material industry-wide volume shift.

Analysis

This is not investable evidence of a category-level demand inflection: the cited national procedure data do not establish acceleration, and the source is a single-provider marketing release. Public aesthetic-medicine equities should therefore not be repriced on a presumed shift away from augmentation; near-term revenue sensitivity for AbbVie (ABBV) and Establishment Labs (ESTA) remains driven by procedure volumes, pricing, financing availability, and surgeon/channel inventory rather than anecdotal consultation mix.

If revision activity broadens over 6-18 months, the economic effect is more nuanced than outright demand destruction. Explant-plus-lift, contouring, and staged fat-transfer cases can carry higher surgeon time and potentially higher patient out-of-pocket spend, but they reduce recurring implant replacement demand and could shift mix toward procedure-adjacent consumables and energy-based skin-tightening vendors. The clearest potential losers would be implant manufacturers with disproportionate exposure to primary augmentation; the likely beneficiaries are diversified aesthetic platforms and independent surgical practices able to monetize multi-step revisions.

The key catalyst is independently reported 2026 procedure-volume data from ASPS, company commentary on US breast-implant unit trends, and elective-procedure financing indicators over the next 1-3 quarters. A meaningful thesis requires evidence that revision growth exceeds primary augmentation declines; absent that, a natural-look narrative is chiefly a mix issue, not an industry growth signal. Falsification for any bearish implant view would be stable-to-rising US implant units and unchanged revision/primary mix in 2026 disclosures.

Key Decisions for Investors

• No directional position on this release; treat it as a watch item until ASPS or public-company channel data show a sustained revision-volume acceleration over at least two quarters.
• Monitor ABBV quarterly aesthetics commentary for breast-implant volume, US elective-procedure demand, and pricing; avoid extrapolating a single-practice narrative into Allergan revenue estimates.
• If independent data confirm revision growth alongside softer primary augmentation, consider a 6-12 month relative-value basket: long diversified aesthetics exposure ABBV versus short higher-beta implant pure-play ESTA, sized modestly given limited disclosure on procedure mix. Exit if implant-unit trends remain positive or the valuation spread widens without estimate revisions.
• Track consumer-credit conditions and high-income discretionary spending as the nearer-term driver of elective surgery demand; deteriorating financing approvals would pressure both primary and revision procedures regardless of aesthetic preference.